Collegium Pharmaceutical

COLLApproved

Stoughton, United StatesFounded 2002collegiumpharma.com

Collegium Pharmaceutical is a U.S.-based biopharmaceutical company with a mission to improve the lives of people living with serious medical conditions. The company has built a commercial portfolio centered on responsible pain management and has recently expanded into ADHD treatment through strategic acquisitions, such as AZSTARYS®. Led by a seasoned executive team with deep industry experience, Collegium is focused on growing its diversified portfolio and maintaining a strong commitment to corporate social responsibility and community impact.

Market Cap

$1.1B

Founded

2002

Focus

Drug Delivery

COLL · Stock Price

USD 35.44+16.11 (+83.34%)

Historical price data

AI Company Overview

Technology Platform

Collegium's strategic platform is centered on portfolio diversification, lifecycle management, and the commercialization of differentiated medications, with a focus on responsible pain management featuring abuse-deterrent properties.

Pipeline Snapshot

3 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Xtampza ER (oxycodone)	Chronic Pain	Approved
HLD200 methylphenidate hydrochloride capsules + Placebo HLD200 capsules	Attention Deficit Hyperactivity Disorder	Phase 3
Oxycodone DETERx + Placebo	Chronic Low Back Pain	Phase 3

Funding History

Total raised: $50M

IPOUndisclosedUndisclosedMay 7, 2015

Series B$30MUndisclosedJun 15, 2005

Series A$20MUndisclosedJun 15, 2003

FDA Approved Drugs

XTAMPZA ERNDAApr 26, 2016

Opportunities

Significant opportunities exist in expanding market share for its ADHD franchise (JORNAY PM and the pending AZSTARYS acquisition) within the large and growing neuropsychiatry market.

Further portfolio diversification through strategic acquisitions in adjacent therapeutic areas presents a clear path for sustained growth beyond its core pain management business.

Risk Factors

Key risks include ongoing litigation and regulatory scrutiny related to opioid marketing, intense competition in the ADHD market from larger pharmaceutical companies, and dependency on successful acquisition integration for future growth rather than a robust internal R&D pipeline.

Competitive Landscape

Collegium competes in pain management against other branded and generic opioid manufacturers, differentiating on responsible stewardship. In ADHD, it faces large, established players like Takeda and Novartis, competing on the specific dosing and efficacy profiles of its products like JORNAY PM.

Publications

Patents

Pipeline

FDA Approvals